Clinical Trial Detail

NCT ID NCT02252042
Title Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors Merck Sharp & Dohme Corp.
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Methotrexate

Cetuximab

Docetaxel

Age Groups: adult

No variant requirements are available.